Pluri (PLUR) Restructuring Costs (2023 - 2024)

Pluri (PLUR) reported Restructuring Costs of -$3000.0 for Q2 2024, down 130.0% quarter-over-quarter from $10000.0 in Q1 2024.

Pluri (PLUR) Restructuring Costs (2023 - 2024) Analysis & Trends

Pluri (PLUR) has 2 years of Restructuring Costs data on file, last reported at -$3000.0 in Q2 2024.

Restructuring Costs for Q2 2024 came in at -$3000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $411000.0 (changed N/A YoY), and the FY2024 annual result was $220000.0, up 3566.67% from the prior year.
Restructuring Costs declined to -$3000.0 in Q2 2024 per PLUR's latest filing, from $10000.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $310000.0 in Q1 2023 and troughed at -$3000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Pluri	21.39 Mn	21.87 Mn	86,000.00

Download Data